EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC-SA 4.0

Comparison of renal function of the patients receiving linagliptin or vildagliptin in uncontrolled type 2 diabetes mellitus: An observational study in the backdrop of the COVID-19 pandemic

Sailayee Chaudhuri, Supreeti Biswas, Sandip Mukhopadhyay, Somnath Dasgupta

Indian Journal of Pharmacology · 2025

DOI: 10.4103/ijp.ijp_492_24 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Indian Journal of Pharmacology, 2025. Verfasst von Sailayee Chaudhuri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, MJN Medical College and Hospital, Coochbehar, West Bengal, India. Hauptthemen laut MEDLINE: Vildagliptin, Diabetes Mellitus, Type 2, Linagliptin, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dipeptidyl peptidase 4 (DPP-4) inhibitors are primarily excreted renally. Linagliptin is an exception with excretion primarily through enterohepatic system and is expected to have a better renal profile, though real-world data are scarce. Comparative studies on the renal safety and glycaemic control with linagliptin versus popular DPP-4 inhibitors such as vildagliptin are crucial, especially in the background of COVID-19 pandemic that hugely impacted glycemic control in India’s large type 2 diabetes mellitus (T2DM) population. MATERIALS AND METHODS: Adult T2DM patients not controlled with metformin alone, added linagliptin (5 mg once daily) or vildagliptin (50 mg twice daily) in the tertiary care outpatient department setting were included in the study. Parameters such as glycosylated hemoglobin, fasting blood glucose, postprandial blood glucose, blood urea nitrogen, serum creatinine, estimated glomerular filtration rate (eGFR), change in renal function, glycemic control, and clinical parameters were compared at baseline, 2 months, and 6 months of treatment. All adverse events were analyzed using the WHO-UMC scale. RESULTS: Both groups achieved similar glycemic control, however, accompanied with impairment of renal parameters after 6 months. Compared to linagliptin, almost 300% rise in creatinine and 140% fall in eGFR were noted in the vildagliptin recipients. However, the difference in serum creatinine or eGFR could not attain statistical significance in the study. CONCLUSION: Both linagliptin and vildagliptin can help to achieve glycemic control despite possible influence of the COVID-19 pandemic and are generally well tolerated. However, renal functions are better preserved with linagliptin. Further studies involving a larger sample size and longer follow-up are recommended before generalization of the findings of the present study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VildagliptinDiabetes Mellitus, Type 2LinagliptinDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsKidneyHumansMaleFemaleMiddle AgedCOVID-19Blood GlucoseIndiaGlomerular Filtration RateAgedGlycated HemoglobinAdult

Stichwörter der Autor:innen

COVID-19Causalitycreatininediabetes mellitusdipeptidyl peptidase 4 inhibitorsestimated glomerular filtration ratelinagliptinrenal functionrenal safetyvildagliptin

Substanzen

VildagliptinLinagliptinDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsBlood GlucoseGlycated Hemoglobin

Autor:innen und Institutionen

  • Department of Pharmacology, MJN Medical College and Hospital, Coochbehar, West Bengal, India.
  • Department of Pharmacology, Burdwan Medical College, Burdwan, West Bengal, India.
  • Department of Pharmacology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India.
  • Department of Pharmacology and Epidemiology, ICMR - National Institute for Research in Bacterial Infections, Kolkata, West Bengal, India.
  • Department of Medicine, Calcutta National Medical College, Kolkata, West Bengal, India.

Zitieren

APA

Chaudhuri, S., Biswas, S., Mukhopadhyay, S., & Dasgupta, S. (2025). Comparison of renal function of the patients receiving linagliptin or vildagliptin in uncontrolled type 2 diabetes mellitus: An observational study in the backdrop of the COVID-19 pandemic. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_492_24

Vancouver

Chaudhuri S, Biswas S, Mukhopadhyay S, Dasgupta S. Comparison of renal function of the patients receiving linagliptin or vildagliptin in uncontrolled type 2 diabetes mellitus: An observational study in the backdrop of the COVID-19 pandemic. Indian Journal of Pharmacology. 2025. doi:10.4103/ijp.ijp_492_24

BibTeX
@article{Chaudhuri2025,
  author = {Chaudhuri, Sailayee and Biswas, Supreeti and Mukhopadhyay, Sandip and Dasgupta, Somnath},
  title = {Comparison of renal function of the patients receiving linagliptin or vildagliptin in uncontrolled type 2 diabetes mellitus: An observational study in the backdrop of the COVID-19 pandemic},
  journal = {Indian Journal of Pharmacology},
  year = {2025},
  doi = {10.4103/ijp.ijp_492_24}
}
Kostenlos starten →